Jinbin Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinbin Wei has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Xing Lin
Guangxi Medical University, Nanning 530021, China
9 shared publications Yuanyuan Wei
Guangxi Medical University, Nanning 530021, China
8 shared publicationsSiyun Chen
Pharmacy Department, The People's Hospital of Hezhou Hezhou China
7 shared publicationsHongmei Su
Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China
6 shared publications- Renbin Huang
Pharmaceutical College, Guangxi Medical University, Nanning, China
6 shared publications Wuchang Zhu
Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China
6 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (4)
Multi‐Omics Analysis Identifies Tryptophan Metabolism and Glycolysis as Potential Pathways Involved in the Protective Effects of Tormentic Acid Against Metabolic Associated Fatty Liver Disease
Metabolic associated fatty liver disease (MAFLD) has high morbidity and tragically lacks effective therapeutic remedies. Tormentic acid (TA) has been shown to have therapeutic effect on liver fibrosis, but its role in MAFLD remains unknown. Therefore, we employed multi‐omics analyses to investigate the effects of TA on MAFLD. In this study, male C57BL/6J mice were fed a methionine‐ and choline‐ deficiency (MCD) diet to induce MAFLD and subsequently treated with TA for 4 weeks. The therapeutic efficacy of TA was then evaluated through histopathological examination and biochemical analysis. In addition, multi‐omics analyses including transcriptomics, proteomics and metabolomics were conducted to identify potential pathways associated with TA treatment. Finally, key genes and proteins in the identified pathways were validated by qPCR and Western blot. Our results showed that TA significantly alleviated liver damage and excessive lipid accumulation. Importantly, our integrative multi‐omics analyses identified tryptophan metabolism and glycolysis as pivotal pathways associated with TA treatment in our fatty liver mouse model. Subsequent validation demonstrated the TA‐induced upregulation of IDO2 and HAAO, suggesting engagement of tryptophan metabolism. Concurrently, TA treatment downregulated HK2, PFKP, and PKM2, indicative of altered rate‐limiting glycolytic enzyme expression. These findings suggest that TA alleviates MCD diet‐induced MAFLD, potentially involving modulation of enzyme expression in tryptophan metabolism and glycolysis.
- 7 August 2026
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 14 (4)
Open AccessMulti‐Omics Analysis Identifies Tryptophan Metabolism and Glycolysis as Potential Pathways Involved in the Protective Effects of Tormentic Acid Against Metabolic Associated Fatty Liver Disease
Metabolic associated fatty liver disease (MAFLD) has high morbidity and tragically lacks effective therapeutic remedies. Tormentic acid (TA) has been shown to have therapeutic effect on liver fibrosis, but its role in MAFLD remains unknown. Therefore, we employed multi‐omics analyses to investigate the effects of TA on MAFLD. In this study, male C57BL/6J mice were fed a methionine‐ and choline‐ deficiency (MCD) diet to induce MAFLD and subsequently treated with TA for 4 weeks. The therapeutic efficacy of TA was then evaluated through histopathological examination and biochemical analysis. In addition, multi‐omics analyses including transcriptomics, proteomics and metabolomics were conducted to identify potential pathways associated with TA treatment. Finally, key genes and proteins in the identified pathways were validated by qPCR and Western blot. Our results showed that TA significantly alleviated liver damage and excessive lipid accumulation. Importantly, our integrative multi‐omics analyses identified tryptophan metabolism and glycolysis as pivotal pathways associated with TA treatment in our fatty liver mouse model. Subsequent validation demonstrated the TA‐induced upregulation of IDO2 and HAAO, suggesting engagement of tryptophan metabolism. Concurrently, TA treatment downregulated HK2, PFKP, and PKM2, indicative of altered rate‐limiting glycolytic enzyme expression. These findings suggest that TA alleviates MCD diet‐induced MAFLD, potentially involving modulation of enzyme expression in tryptophan metabolism and glycolysis.
- Open Access
- 11 June 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Development and validation of a LightGBM-based model with risk stratification for predicting early recurrence after catheter ablation for atrial fibrillation
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia, yet tools for predicting early recurrence (ER) after catheter ablation remain limited. This study aimed to develop a machine learning model to estimate ER risk following first-time AF ablation. In this retrospective single-center study, 519 patients undergoing initial AF ablation were enrolled (ER rate: 9.2%). Eight predictors were selected via recursive feature elimination. A LightGBM model was constructed and internally validated against logistic regression and conventional risk scores. The LightGBM model achieved an AUC of 0.715 in training and 0.704 in testing, showing higher discrimination than logistic regression (AUC = 0.623) and traditional scores (APPLE AUC = 0.560). SHAP analysis identified mitral regurgitation severity, age, hemoglobin, and albumin as predominant predictors. Using a Youden-derived threshold (0.099), high- and low-risk groups exhibited significantly different recurrence rates in testing(11.4% vs. 2.9%; P < 0.05). We developed a LightGBM-based model integrating structural and metabolic features that modestly improves upon conventional approaches in predicting ER after AF ablation. This tool may facilitate personalized post-procedural management. Multicenter prospective validation is warranted.
- 11 June 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessDevelopment and validation of a LightGBM-based model with risk stratification for predicting early recurrence after catheter ablation for atrial fibrillation
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia, yet tools for predicting early recurrence (ER) after catheter ablation remain limited. This study aimed to develop a machine learning model to estimate ER risk following first-time AF ablation. In this retrospective single-center study, 519 patients undergoing initial AF ablation were enrolled (ER rate: 9.2%). Eight predictors were selected via recursive feature elimination. A LightGBM model was constructed and internally validated against logistic regression and conventional risk scores. The LightGBM model achieved an AUC of 0.715 in training and 0.704 in testing, showing higher discrimination than logistic regression (AUC = 0.623) and traditional scores (APPLE AUC = 0.560). SHAP analysis identified mitral regurgitation severity, age, hemoglobin, and albumin as predominant predictors. Using a Youden-derived threshold (0.099), high- and low-risk groups exhibited significantly different recurrence rates in testing(11.4% vs. 2.9%; P < 0.05). We developed a LightGBM-based model integrating structural and metabolic features that modestly improves upon conventional approaches in predicting ER after AF ablation. This tool may facilitate personalized post-procedural management. Multicenter prospective validation is warranted.
- 16 January 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (1) , e70239
Network Pharmacology‐Based Analysis and In Vitro Experiments Validation Reveal Tormentic Acid Induces Apoptosis via PI3K / AKT / HSP90 Pathway in HepG2 Cells
Tormentic acid (TA) has demonstrated potential anti‐hepatocellular carcinoma (HCC) effects. This study aimed to explore the anti‐HCC effect and underlying mechanisms of TA via network pharmacology, molecular docking, molecular dynamics simulation and in vitro experiments. In this study, HCC‐related genes were obtained from the GeneCards OMIM, and GEO databases. The targets of TA were collected from Swiss Target Prediction, TargetNet, and the PharmMapper database. A protein–protein interaction network of TA anti‐HCC target genes was constructed using the STRING database and visualized by Cytoscape. The potential anti‐HCC targets of TA were then identified through GO and KEGG pathway enrichment analyses using the DAVID database. Molecular docking and molecular dynamics simulation were performed to evaluate the binding affinity and structural stability of TA‐target complexes. For the in vitro experiments, the CCK‐8 assay was employed to assess the effects of TA on HepG2 cell viability. Apoptosis in HepG2 cells was detected via flow cytometry. Western blotting was used to elucidate the underlying molecular mechanisms of TA. Integrating network pharmacology and bioinformatics analyses revealed that the anti‐HCC effect of TA was closely associated with apoptosis and the PI3K/AKT/HSP90 pathway. Molecular docking and molecular dynamics simulation demonstrated that TA‐target protein complexes maintained marked structural stability and exhibited favorable kinetic properties. In vitro experiments showed that TA significantly inhibited the proliferation of HepG2 cells and induced apoptosis. Western blot results further indicated that TA treatment increased the expression of Bax while decreasing the expression levels of PI3K, AKT, HSP90, and Bcl‐2. TA suppressed the proliferation of HepG2 cells and induced apoptosis, possibly by regulating the PI3K/AKT/HSP90 signaling pathway.
- 16 January 2026
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 107 (1) , e70239
Network Pharmacology‐Based Analysis and In Vitro Experiments Validation Reveal Tormentic Acid Induces Apoptosis via PI3K / AKT / HSP90 Pathway in HepG2 Cells
Tormentic acid (TA) has demonstrated potential anti‐hepatocellular carcinoma (HCC) effects. This study aimed to explore the anti‐HCC effect and underlying mechanisms of TA via network pharmacology, molecular docking, molecular dynamics simulation and in vitro experiments. In this study, HCC‐related genes were obtained from the GeneCards OMIM, and GEO databases. The targets of TA were collected from Swiss Target Prediction, TargetNet, and the PharmMapper database. A protein–protein interaction network of TA anti‐HCC target genes was constructed using the STRING database and visualized by Cytoscape. The potential anti‐HCC targets of TA were then identified through GO and KEGG pathway enrichment analyses using the DAVID database. Molecular docking and molecular dynamics simulation were performed to evaluate the binding affinity and structural stability of TA‐target complexes. For the in vitro experiments, the CCK‐8 assay was employed to assess the effects of TA on HepG2 cell viability. Apoptosis in HepG2 cells was detected via flow cytometry. Western blotting was used to elucidate the underlying molecular mechanisms of TA. Integrating network pharmacology and bioinformatics analyses revealed that the anti‐HCC effect of TA was closely associated with apoptosis and the PI3K/AKT/HSP90 pathway. Molecular docking and molecular dynamics simulation demonstrated that TA‐target protein complexes maintained marked structural stability and exhibited favorable kinetic properties. In vitro experiments showed that TA significantly inhibited the proliferation of HepG2 cells and induced apoptosis. Western blot results further indicated that TA treatment increased the expression of Bax while decreasing the expression levels of PI3K, AKT, HSP90, and Bcl‐2. TA suppressed the proliferation of HepG2 cells and induced apoptosis, possibly by regulating the PI3K/AKT/HSP90 signaling pathway.
- Retraction
- 19 December 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 170, 116063
Retraction notice to Corrigendum to “Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway” [Int. Immunopharmacol. 75 (2019) 105759]
- 19 December 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 170, 116063
RetractionRetraction notice to Corrigendum to “Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway” [Int. Immunopharmacol. 75 (2019) 105759]
- 20 April 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (1) , 312-324
Multi-functional Chitosan Polymeric Micelles for improving the oral bioavailability of Paclitaxel based on synergistic effect
A novel multi-functional micelle delivery system was developed for enhancing the oral absorption of paclitaxel (PTX). The delivery carriers were constructed by modifying chitosan-stearic acid (CS-SA) micelles with L-carnitine (LC) and co-encapsulating quercetin (Que), and the PTX-loaded micelles were prepared by film-sonication dispersing technique. The as-prepared micelles showed homogeneous spherical shapes with a small particle size of 148.3 ± 1.7 nm, high drug loading of 7.05% and low critical micelle concentration (CMC) of 16.89 µg/ml. Compared to the in-house PTX formulation similar to the commercial injection Taxol™, the target PTX-loaded micelles had obvious sustained-release effects and exhibited an oral relative bioavailability of 168.08%. The cellular uptake studies of Caco-2 cells confirmed the micellar modification of LC and the co-loading of Que played important roles in promoting the absorption of drug loaded in micelles. The CYP3A4 enzyme test demonstrated the micelles had an inhibitory effect on the metabolic enzyme due to the presence of Que. These findings confirmed the potential of the multi-functional chitosan polymeric micelles based on synergistic effect as an effective oral delivery system. Graphical abstract
- 20 April 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (1) , 312-324
Multi-functional Chitosan Polymeric Micelles for improving the oral bioavailability of Paclitaxel based on synergistic effect
A novel multi-functional micelle delivery system was developed for enhancing the oral absorption of paclitaxel (PTX). The delivery carriers were constructed by modifying chitosan-stearic acid (CS-SA) micelles with L-carnitine (LC) and co-encapsulating quercetin (Que), and the PTX-loaded micelles were prepared by film-sonication dispersing technique. The as-prepared micelles showed homogeneous spherical shapes with a small particle size of 148.3 ± 1.7 nm, high drug loading of 7.05% and low critical micelle concentration (CMC) of 16.89 µg/ml. Compared to the in-house PTX formulation similar to the commercial injection Taxol™, the target PTX-loaded micelles had obvious sustained-release effects and exhibited an oral relative bioavailability of 168.08%. The cellular uptake studies of Caco-2 cells confirmed the micellar modification of LC and the co-loading of Que played important roles in promoting the absorption of drug loaded in micelles. The CYP3A4 enzyme test demonstrated the micelles had an inhibitory effect on the metabolic enzyme due to the presence of Que. These findings confirmed the potential of the multi-functional chitosan polymeric micelles based on synergistic effect as an effective oral delivery system. Graphical abstract
- Open Access
- 19 April 2024
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 12 (5) , 481-495
Astragalus Polysaccharide Enhances Voriconazole Metabolism under Inflammatory Conditions through the Gut Microbiota
Voriconazole (VRC), a widely used antifungal drug, often causes hepatotoxicity, which presents a significant clinical challenge. Previous studies demonstrated that Astragalus polysaccharide (APS) can regulate VRC metabolism, thereby potentially mitigating its hepatotoxic effects. In this study, we aimed to explore the mechanism by which APS regulates VRC metabolism.
- 19 April 2024
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 12 (5) , 481-495
Open AccessAstragalus Polysaccharide Enhances Voriconazole Metabolism under Inflammatory Conditions through the Gut Microbiota
Voriconazole (VRC), a widely used antifungal drug, often causes hepatotoxicity, which presents a significant clinical challenge. Previous studies demonstrated that Astragalus polysaccharide (APS) can regulate VRC metabolism, thereby potentially mitigating its hepatotoxic effects. In this study, we aimed to explore the mechanism by which APS regulates VRC metabolism.
- 12 February 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 129, 111667
Corrigendum to “2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from the root of Averrhoa carambola L., protects against diabetic kidney disease by inhibiting TLR4/TGFβ signaling pathway” [Int. Immunopharmacol. 80 (2020) 106120]
- 12 February 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 129, 111667
Corrigendum to “2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione, isolated from the root of Averrhoa carambola L., protects against diabetic kidney disease by inhibiting TLR4/TGFβ signaling pathway” [Int. Immunopharmacol. 80 (2020) 106120]
- 22 September 2023
- Published by Elsevier in Phytomedicine
- Vol. 121, 155117
Isovitexin alleviates hepatic fibrosis by regulating miR-21-mediated PI3K/Akt signaling and glutathione metabolic pathway: based on transcriptomics and metabolomics
- 22 September 2023
- Published by Elsevier in Phytomedicine
- Vol. 121, 155117
Isovitexin alleviates hepatic fibrosis by regulating miR-21-mediated PI3K/Akt signaling and glutathione metabolic pathway: based on transcriptomics and metabolomics
- 5 June 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 402-417
Asiatic acid ameliorates rifampicin and isoniazid‐induced liver injury in vivo by regulating sphingolipid metabolism and mitogen‐activated protein kinase signaling pathways
In this study, we aimed to determine whether asiatic acid (AA) exerts any therapeutic effects on rifampicin (RFP)- and isoniazid (INH)-induced liver injury and elucidate the underlying mechanisms. Briefly, liver injury in mice was induced via RFP and INH administration. We investigated the effects and potential action mechanisms of AA on liver injury using transcriptomics, metabolomics and various examinations. We found that AA significantly ameliorated the pathological changes in liver tissues and decreased the transaminase activity, inflammation and oxidative stress damage. Transcriptomics revealed 147 differentially expressed genes (DEGs) between the AA and model groups that were enriched in metabolic and mitogen-activated protein kinase (MAPK) signalling pathways. Metabolomics revealed 778 differentially expressed metabolites between the AA and model groups. Furthermore, integrated transcriptomics and metabolomics analyses revealed strong correlations between DEGs and differentially expressed metabolites and indicated that AA regulates the sphingolipid metabolism by inhibiting the expression of delta 4-desaturase, sphingolipid 1. Experimental results confirmed that AA inhibited the MAPK signalling pathway. In summary, AA inhibits inflammation and oxidative stress damage by regulating the sphingolipid metabolism pathway and blocking the MAPK signalling pathway, thereby relieving the RFP/INH-induced liver injury.
- 5 June 2023
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 133 (4) , 402-417
Asiatic acid ameliorates rifampicin and isoniazid‐induced liver injury in vivo by regulating sphingolipid metabolism and mitogen‐activated protein kinase signaling pathways
In this study, we aimed to determine whether asiatic acid (AA) exerts any therapeutic effects on rifampicin (RFP)- and isoniazid (INH)-induced liver injury and elucidate the underlying mechanisms. Briefly, liver injury in mice was induced via RFP and INH administration. We investigated the effects and potential action mechanisms of AA on liver injury using transcriptomics, metabolomics and various examinations. We found that AA significantly ameliorated the pathological changes in liver tissues and decreased the transaminase activity, inflammation and oxidative stress damage. Transcriptomics revealed 147 differentially expressed genes (DEGs) between the AA and model groups that were enriched in metabolic and mitogen-activated protein kinase (MAPK) signalling pathways. Metabolomics revealed 778 differentially expressed metabolites between the AA and model groups. Furthermore, integrated transcriptomics and metabolomics analyses revealed strong correlations between DEGs and differentially expressed metabolites and indicated that AA regulates the sphingolipid metabolism by inhibiting the expression of delta 4-desaturase, sphingolipid 1. Experimental results confirmed that AA inhibited the MAPK signalling pathway. In summary, AA inhibits inflammation and oxidative stress damage by regulating the sphingolipid metabolism pathway and blocking the MAPK signalling pathway, thereby relieving the RFP/INH-induced liver injury.